[Federal Register Volume 61, Number 145 (Friday, July 26, 1996)]
[Notices]
[Pages 39141-39142]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-18969]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for U.S. companies and may also be available for licensing.
ADDRESS: Licensing information and copies of the U.S. patent
applications and issued patents listed below may be obtained by
contacting Cindy K. Fuchs, J.D., at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301/496-7735 ext 232; fax:
301/402-0220. A signed Confidential Disclosure Agreement will be
required to receive copies of the patent applications.
Inhibition of Retroviral LTR Promoters by Calcium Response Modifiers
EC Kohn, LA Liotta, KL Gardner (NCI)
Filed 12 Dec 94
Serial No. 08/353,765
The pathogenesis of HIV infection can be divided into two phases
based upon the activity of the HIV virus. The latent phase is
characterized by low transciptional activity and/or low
[[Page 39142]]
replication frequency of the virus whereas the lytic phase is
characterized by high transcriptional activity and/or high replication
frequency. Although the mechanism(s) involved in the switch from the
latent to lytic phase is not completely understood, inhibition of the
viral LTR promoter is an important strategy in AIDS treatment. The
invention concerns the use of the compound carboxyamidotriazole (CAI),
a calcium response modifier, and structurally related compounds that
are capable of preventing the activation of the LTR promoter in the
treatment of HIV infection and AIDS. In addition, CAI has
antimetastatic properties and currently is being tested in clinical
trials for the treatment of cancer. A further advantage is that CAI has
shown no severe side effects during these trials. Therefore treatment
of AIDS patients with CAI would also allow for the treatment of related
cancers such as Kaposi's sarcoma. (portfolio: Infectious Diseases--
Therapeutics, anti-virals, AIDS)
Diastereoselective Process Leading to a Key Intermediate for the
Preparation of Fluorinated Reverse Transcriptase Inhibitors
VE Marquez, JS Driscoll, MA Siddiqui (NCI)
Serial No. 08/189,095 filed 31 Jan 94
U.S. Patent No. 5,498,719 issued 12 Mar 96
A novel process has been developed for synthesizing a key
intermediate in the preparation of fluorinated reverse transcriptase
inhibitors. Recently, several fluorinated dideoxynucleotides have been
found to be effective inhibitors of reverse transcriptase and, thus,
offer promise for replacing or augmenting current drugs for the
treatment of HIV-1 infection; however, chemically synthesizing these
fluorinated dideoxynucleotides is quite expensive, making it
economically difficult to produce large-scale amounts for testing. This
new process allows the synthesis of a key intermediate in the
production of fluorinated dideoxynucleotides at much lower costs
because the reaction is diastereoselective, meaning that there are
fewer side reactions and more primary product is produced. (portfolio:
Infectious Diseases--Therapeutics, anti-virals, AIDS)
C-C Chemokines That Inhibit Retrovirus Infection
P Lusso, R Gallo, F Cocchi, A De Vico, A Garzino-Demo (NCI)
Filed 30 Nov 95
DHHS Reference No. E-008-96/0
This invention concerns three members of the human C-C chemokine
family, RANTES, macrophage inflammatory protein 1 (MIP-
1) and macrophage inflammatory protein 1 (MIP-
1), which are produced and secreted by several cell types,
including CD8-positive T lymphocytes, and which act in vitro as HIV
suppressive factors. These factors and their respective genes may be
used in the diagnosis, prognosis, treatment and prevention of AIDS and
other retrovirus-induced diseases. The invention provides a therapeutic
preparation, methods for therapeutic and prophylactic treatment of
retroviral infection, and a method of prognosis for retroviral
infection. The technology was reported in BioWorld Today (6(234):1
(December 7, 1995) and Science 270(8):1560-1561 (December 8, 1995).
(portfolio: Infectious Diseases--Therapeutics, anti-virals, AIDS;
Infectious Diseases--Diagnostics, viral, AIDS)
Dated: July 16, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-18969 Filed 7-25-96; 8:45 am]
BILLING CODE 4140-01-M
